Welcome to our dedicated page for Orthofix Med SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orthofix Medical Inc. (NASDAQ: OFIX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Orthofix is a global medical technology company focused on spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, and its filings offer detailed insight into these operations.
Orthofix uses current reports on Form 8-K to announce material events such as quarterly financial results, non-GAAP financial measure discussions, and outcomes of its annual meeting of shareholders. Recent 8-K filings describe how the company reports net sales by category, including Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics, and explain non-GAAP measures like constant currency, free cash flow, adjusted gross profit, adjusted net income (loss) and adjusted EBITDA.
Through SEC filings, Orthofix also discloses information on topics such as restructuring costs and impairments related to its M6 artificial disc product lines, merger-related costs associated with SeaSpine, and other adjustments that management excludes when evaluating underlying performance. Governance-related filings, including those covering the annual meeting, document director elections, advisory votes on executive compensation, auditor ratification and board committee appointments.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand segment reporting, non-GAAP adjustments, capital structure details and governance decisions. Users can monitor new 8-Ks and other forms as they are posted to EDGAR, and use the summaries to navigate Orthofix’s financial and regulatory history more efficiently.
Michael Finegan, Director at Orthofix Medical, reported acquiring 26,087 deferred stock units (DSUs) on June 18, 2025. The DSUs were granted at $0 and will fully vest on the first anniversary of the grant date, contingent on Finegan's continued service.
Following this transaction, Finegan beneficially owns a total of 57,391 securities, which includes:
- 26,087 newly granted DSUs
- 29,718 previously reported DSUs
- 1,586 shares acquired through Orthofix's Stock Purchase Plan on April 30, 2025
The DSUs represent a contingent right to receive one share of common stock each, with settlement occurring within 45 days of Finegan's termination of service with Orthofix. This Form 4 filing was submitted by attorney-in-fact J. Andres Cedron on June 23, 2025.
Orthofix Medical Inc. (OFIX) – Form 4 Insider Activity
Director Michael E. Paolucci filed a Form 4 reporting the grant of 18,841 deferred stock units (DSUs) on 06/18/2025. The transaction is coded “A,” indicating an acquisition from the issuer at $0 cost as part of equity compensation. Each DSU converts into one share of common stock and vests 100 % on the first anniversary of the grant, subject to continued board service. Vested units will be settled in common shares within 45 days after the director’s service ends.
After the award, Paolucci’s total reported beneficial ownership is 86,948 OFIX shares, which now comprises:
- 54,700 previously reported DSUs
- 1,341 shares purchased through the company’s Stock Purchase Plan on 10/31/2024
- The newly granted 18,841 DSUs
The filing shows no dispositions or sales and does not involve derivative securities other than the DSUs described. No exercise price, expiration, or cash outflow is associated with the grant. The form was signed by attorney-in-fact Geoffrey Gillespie on 06/23/2025.
Because the transaction is a routine equity award to a non-employee director, it does not directly alter Orthofix’s financial position. However, it modestly increases insider ownership, which some investors view as an indicator of alignment between the board and shareholders.
Orthofix Medical (NASDAQ:OFIX) filed a Form 4 disclosing that director Vickie L. Capps was granted 18,841 deferred stock units on 18 June 2025. These units vest in full one year after the grant date, contingent upon continued board service, and will convert into common shares within 45 days of her separation from the company. Following the award, Capps’ reported beneficial ownership increased to 21,934 shares, which includes 3,093 previously disclosed units. The award carries no purchase price and no insider sales were reported.
Orthofix Medical (NASDAQ: OFIX) filed a routine Form 4 disclosing that director Wayne Burris was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost as part of board compensation. The award vests in full one year after the grant date, provided continued service, and will convert to common stock within 45 days after the director leaves the board.
Following the grant, Burris’ total beneficial ownership increased to 50,539 shares, which includes 25,315 previously reported DSUs. The filing reports no share sales, cash proceeds, or changes to Orthofix’s operations or financial outlook.
Orthofix Medical (NASDAQ:OFIX) submitted a routine Form 4 disclosing that director Alan Lee Bazaar received 18,841 deferred stock units on 06/18/2025 as part of standard board compensation.
The units vest in full on the first anniversary of the grant date, contingent upon continued service, and convert into common stock within 45 days of the director’s termination of service. The transaction price is recorded as $0, indicating a non-cash equity award. After the grant, Bazaar beneficially owns 49,824 shares, which include 24,088 previously reported deferred stock units. No shares were sold or disposed of, and the filing notes no other material changes.
Orthofix Medical (OFIX) filed a Form 4 disclosing that director Charles R. Kummeth was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost. The DSUs vest in full on the first anniversary of the grant date and will convert into common stock within 45 days after his service with the company ends. Following the award, Kummeth’s total beneficial ownership rose to 59,237 shares, which now includes 23,502 previously reported DSUs and 1,894 shares accumulated through Orthofix’s Stock Purchase Plan.
Orthofix Medical Inc. (OFIX) – Form 4 insider filing dated 06/23/2025
Director John B. Henneman III reported a single equity-compensation transaction that occurred on 06/18/2025.
- Securities granted: 18,841 deferred stock units (DSUs) coded “A” (award).
- Price: $0, confirming the grant was part of the company’s director compensation plan rather than an open-market purchase or sale.
- Vesting schedule: DSUs vest 100 % on the first anniversary of the grant provided the director continues in service. Each DSU converts into one share of common stock within 45 days after the director’s service ends.
- Post-transaction beneficial ownership: 83,706 OFIX common shares, comprising the newly granted 18,841 DSUs, 29,506 previously reported DSUs, and 951 shares acquired under the Orthofix Stock Purchase Plan on 04/30/2025.
- The filing was executed by attorney-in-fact J. Andres Cedron and submitted on 06/23/2025.
No derivative securities were reported in Table II, and the filing indicates a single reporting person with director status. The form contains no indication of a 10b5-1 trading plan and no amendments to earlier filings.